These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 3497804

  • 1. Comparative antibacterial activity of the new oral cephalosporin BMY-28100.
    Kayser FH.
    Eur J Clin Microbiol; 1987 Jun; 6(3):309-12. PubMed ID: 3497804
    [Abstract] [Full Text] [Related]

  • 2. In vitro activity and beta-lactamase stability of the oral cephalosporin BMY-28100.
    Hiraoka M, Masuyoshi S, Tomatsu K, Inoue M, Mitsuhashi S.
    Eur J Clin Microbiol; 1987 Oct; 6(5):559-63. PubMed ID: 3501756
    [Abstract] [Full Text] [Related]

  • 3. BMY 28100, a new oral cephalosporin.
    Leitner F, Pursiano TA, Buck RE, Tsai YH, Chisholm DR, Misiek M, Desiderio JV, Kessler RE.
    Antimicrob Agents Chemother; 1987 Feb; 31(2):238-43. PubMed ID: 3105449
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of BMY 28100, a new oral cephalosporin.
    Steele J, Edwards B, Rissing J.
    Eur J Clin Microbiol; 1987 Feb; 6(1):111-3. PubMed ID: 3494601
    [Abstract] [Full Text] [Related]

  • 5. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S, Blais J, Hoang M, Dinh C, Cotter D, Bond E, Gannon C, Park C, Malouin F, Dudley MN.
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [Abstract] [Full Text] [Related]

  • 6. In vitro activity of cefprozil (BMY 28100) and cefepime (BMY 28142) against Streptococcus pneumoniae, Branhamella catarrhalis, and Haemophilus influenzae, and provisional interpretive criteria for disk diffusion and dilution susceptibility tests with Haemophilus influenzae.
    Doern GV, Vautour R.
    Diagn Microbiol Infect Dis; 1992 May; 15(7):633-40. PubMed ID: 1424521
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species.
    Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA, Jones RN.
    Diagn Microbiol Infect Dis; 2000 Jun; 37(2):99-105. PubMed ID: 10863104
    [Abstract] [Full Text] [Related]

  • 8. BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.
    Jones RN, Barry AL.
    Diagn Microbiol Infect Dis; 1988 Jan; 9(1):11-26. PubMed ID: 3259489
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of the new oral cephalosporin BMY-28100.
    Aldridge KE, Schiro DD, Sanders CV.
    Eur J Clin Microbiol; 1987 Apr; 6(2):170-2. PubMed ID: 3595580
    [Abstract] [Full Text] [Related]

  • 10. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
    Peric M, Browne FA, Jacobs MR, Appelbaum PC.
    Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
    [Abstract] [Full Text] [Related]

  • 11. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR, Huang WK, Shyr JM, Lau YJ, Liu YC, Luh KT.
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [Abstract] [Full Text] [Related]

  • 12. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of the novel cephalosporin LB 11058 against multidrug-resistant Staphylococci and Streptococci.
    Sader HS, Johnson DM, Jones RN.
    Antimicrob Agents Chemother; 2004 Jan; 48(1):53-62. PubMed ID: 14693518
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [Abstract] [Full Text] [Related]

  • 15. Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens.
    Simor AE, Fuller SA, Low DE.
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2283-6. PubMed ID: 2127351
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of BMY-28100, a new oral cephalosporin.
    Norden CW, Niederriter K.
    Chemotherapy; 1988 Nov; 34(1):27-9. PubMed ID: 3258231
    [Abstract] [Full Text] [Related]

  • 17. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN, Sader HS, Fritsche TR, Pottumarthy S.
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro evaluation of a novel orally administered cephalosporin (Cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
    Jones RN, Biedenbach DJ, Croco MA, Barrett MS.
    Diagn Microbiol Infect Dis; 1998 Aug; 31(4):573-8. PubMed ID: 9764398
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.